Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q3 FY25 results · Oct–Dec 2024
Lincoln Pharmaceuticals reported revenue from operations of ₹146.55 crore (up 0.1% from Q3 FY24) and net profit of ₹20.77 crore (down 25.9% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 146.55 | 146.45 | +0.1% | 161.21 | −9.1% |
| Other income | 8.97 | 11.02 | −18.6% | 9.98 | −10.1% |
| Total income | 155.52 | 157.47 | −1.2% | 171.19 | −9.2% |
| Profit before tax | 28.68 | 37.71 | −23.9% | 34.78 | −17.5% |
| Net profit for the period | 20.77 | 28.04 | −25.9% | 26.33 | −21.1% |
| EPS, basic (₹) | 10.37 | 14.00 | −25.9% | 13.15 | −21.1% |
| Net margin (%) | 14.2 | 19.1 | 16.3 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 146.55 | 146.45 | +0.1% | 161.21 | −9.1% |
| Other income | 8.97 | 11.02 | −18.6% | 9.98 | −10.1% |
| Total income | 155.52 | 157.47 | −1.2% | 171.19 | −9.2% |
| Profit before tax | 28.68 | 37.71 | −23.9% | 34.78 | −17.5% |
| Net profit for the period | 20.77 | 28.04 | −25.9% | 26.33 | −21.1% |
| EPS, basic (₹) | 10.37 | 14.00 | −25.9% | 13.15 | −21.1% |
| Net margin (%) | 14.2 | 19.1 | 16.3 |
Consolidated
- Filed with BSE
- 13 Feb 2025, 13:31 IST
- Board meeting
- 13 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Feb 2025, 13:31 IST
- Board meeting
- 13 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE